Effect of perioperative blood transfusion on outcome in patients with surgically resected lung cancer.
Three hundred thirty patients with non-small cell lung cancer were evaluated to assess the effect of perioperative blood transfusion on overall survival and time to recurrence. One hundred sixty-nine patients received blood products during the perioperative period, and 161 received none. The mean length of follow-up was 3.6 years. There were 90 recurrences, including second primaries, and 99 deaths in the group receiving transfusion; in the group without transfusion, recurrent cancer developed in 74 patients, and 68 died. Survival comparisons, adjusted for stage and cell type using the stratified log-rank statistic, showed significant reduction in survival (p = 0.007) for patients receiving transfusion. Time to recurrence was shorter for patients receiving transfusion (p = 0.035), but became less significant when adjusted for both cell type and stage (p = 0.11). Blood transfusion within the perioperative period appears to have an adverse effect on survival and recurrence in patients undergoing surgical resection for lung cancer.
Moores
D W
DW
Division of Cardiothoracic Surgery, Albany Medical College, NY 12208.
Piantadosi
S
S
McKneally
M F
MF
D001803:Blood Transfusion; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000601:surgery*; D006801:Humans; D007430:Intraoperative Care; D008175:Lung Neoplasms / Q000401:mortality / Q000601:surgery*; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000401:mortality; D011013:Pneumonectomy; D011182:Postoperative Care; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D065227:Transfusion Reaction